There are 2137 resources available
LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Presenter: Erica Mayer
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
161O - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
Presenter: Monica Arnedos
Session: Proffered Paper - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
CN34 - Management of immunotherapy toxicities: A new challenge
Presenter: Laura Bascuñana Sanchez
Session: EONS13: Immunotherapy and precision oncology: What do patients need?
Resources:
Abstract
Slides
Webcast
CN20 - Oral targeted therapy dose adaptation in geriatric cancer patients: A real life French cohort
Presenter: Fanny Leenhardt
Session: EONS13: Phase I clinical trials: What does this mean for our patients?
Resources:
Abstract
Slides
Webcast
1160O - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis
Presenter: Guillaume Nicolas
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1157O - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Presenter: Jaume Capdevila
Session: Proffered Paper - NETs
Resources:
Abstract
Slides
Webcast
1019O - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
Presenter: Nehal Lakhani
Session: Proffered Paper - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
1257O - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Presenter: David Hong
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
1258O - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Presenter: Byoung Chul Cho
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast
LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Presenter: Li Zhang
Session: Proffered Paper - NSCLC metastatic 1
Resources:
Abstract
Slides
Webcast